Metastatic Colorectal Cancer Clinical Trials in Shanghai, Shanghai Municipality
9 recruitingShanghai, Shanghai Municipality, China
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD190 enrolled63 locationsNCT05652894
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled263 locationsNCT07221357
Recruiting
Phase 2
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
Metastatic Colorectal Cancer (CRC)
Fudan University119 enrolled1 locationNCT06856187
Recruiting
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal CancerBRAF V600 Mutation
Fudan University100 enrolled1 locationNCT06749015
Recruiting
Phase 2
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.130 enrolled1 locationNCT06493760
Recruiting
Phase 2
Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
Microsatellite Stable Metastatic Colorectal Cancer
Fudan University96 enrolled1 locationNCT06525428
Recruiting
Phase 2
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Metastatic Colorectal Cancer
Fudan University44 enrolled1 locationNCT05229003
Recruiting
Phase 1
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital78 enrolled1 locationNCT06225622
Recruiting
Phase 2
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Metastatic Colorectal Cancer
Fudan University101 enrolled1 locationNCT05970705